Financial annual reports
Explore the complete set of QIAGEN’s 2024 financial reports and regulatory filings — your central resource for validated financial information.
Additional reports
QIAGEN 2024 results at a glance
$0
billion 2024 net sales
$0
CER adjusted diluted EPS
>0
countries served with our products
>0
customers worldwide
Sharpening focus on pillars for profitable growth
QIAGEN continues to prioritize and accelerate investments for growth in QIAcuity digital PCR (dPCR), QIAstat-Dx syndromic testing, and our QDI (QIAGEN Digital Insights) portfolio. At the same time, we are building on our strong and proven leadership in Sample technologies and QuantiFERON, capitalizing on consistent demand and trusted market positions. Together, these strategic pillars form the foundation for sustainable, profitable growth and long-term value creation.
